Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies for chronic hepatitis B virus (HBV) infection. The company operates within the biotechnology and life sciences industries, with its core mission centered on achieving a functional cure for HBV. Its primary revenue drivers historically have included licensing arrangements, collaboration agreements, and milestone or royalty-related income rather than product sales, as it does not currently have an approved commercial therapy.
Arbutus has developed a diversified antiviral pipeline targeting multiple mechanisms of the HBV lifecycle, including RNA interference, capsid inhibition, and immune modulation. The company is strategically positioned through its proprietary delivery technologies and foundational intellectual property related to lipid nanoparticle (LNP) systems, which have been widely licensed within the pharmaceutical industry. Arbutus traces its origins to Tekmira Pharmaceuticals, founded in 2005, and underwent a strategic transformation and rebranding in 2015 to focus specifically on HBV therapeutics following the spin-out of certain non-core assets.
Business Operations
Arbutus conducts its operations primarily through research and development activities focused on HBV drug candidates. Its business is organized around HBV therapeutics development, encompassing small-molecule antivirals, RNA-targeting approaches, and combination therapy strategies. Key product candidates have included capsid inhibitors, RNAi-based agents, and oral compounds designed to suppress viral replication and reduce viral antigens. Revenue generation has largely come from licensing intellectual property and settlement-related royalty streams rather than ongoing product sales.
The company’s operations are primarily based in the United States, with laboratory and administrative functions supported by external contract research organizations and manufacturing partners. Arbutus controls a significant portfolio of patents related to LNP delivery technology and has entered into licensing agreements with major pharmaceutical companies. It does not currently operate manufacturing facilities at commercial scale and relies on third parties for clinical trial execution and production.
Strategic Position & Investments
Arbutus’s strategic direction is focused on advancing combination therapies that address multiple barriers to curing chronic HBV infection. The company has prioritized internal pipeline advancement while selectively monetizing non-core assets, particularly its LNP intellectual property. A key strategic event was the monetization of certain LNP-related rights and settlements that resulted in ongoing royalty interests tied to approved mRNA-based products developed by third parties.
The company has made targeted investments in early- and mid-stage HBV programs rather than broad-based acquisitions, maintaining a capital-efficient model. Genevant Sciences, a company co-founded by Arbutus to develop nucleic acid-based medicines, represents a notable strategic relationship, with Arbutus retaining economic interests. Arbutus remains focused on emerging antiviral technologies and immune-modulating approaches that could complement existing standard-of-care HBV treatments.
Geographic Footprint
Arbutus Biopharma Corporation is headquartered in the United States, with its principal executive offices located in Pennsylvania. Its operational footprint is primarily North American, with research activities coordinated domestically and supported by international clinical trial sites as required for HBV studies.
While the company does not maintain extensive physical infrastructure outside the U.S., its influence is global due to international licensing agreements, worldwide patent coverage, and clinical development programs that may include trial sites in Asia, Europe, and other regions with high HBV prevalence. Its royalty interests and intellectual property reach extend across multiple continents through partnerships with multinational pharmaceutical companies.
Leadership & Governance
Arbutus is led by an executive team with experience in antiviral drug development, corporate strategy, and biotechnology commercialization. The leadership emphasizes scientific rigor, disciplined capital allocation, and long-term value creation through innovation in HBV therapeutics. Governance is overseen by a board of directors with backgrounds in biopharma, finance, and public company oversight.
Key executives include:
- William Collier – President and Chief Executive Officer
- David Hastings – Chief Financial Officer
- Lindsay McHutchison – Chief Scientific Officer
- Lucinda “Lucy” Hone – Chief Operating Officer
- Mark Velleca – Board Chair
The leadership team’s strategic vision centers on advancing differentiated HBV combination therapies while leveraging the company’s intellectual property portfolio to support financial sustainability.